Chronic HCV-infection is common in hemodialysis patients and increases a risk of unfavorable outcomes prior and after kidney transplantation. Efficacyofcombination antiviral treatment with pegylated interferon-alfa and low-dose ribavirin in dialysis patients with chronic hepatitis C is limited. Daclatasvir and asunaprevir are novel direct acting antiviral agents. Both medications are mainly eliminated through liver and can be administered to dialysis patients. In the first clinical studies, sustained viologic response rate after antiviral treatment with daclatasvir and asunaprevir in dialysis patients infected with HCV 1b was up to 95-100% and was similar to that in patienths without kidney dysfuction.
HCV-infection, dialysis, antiviral treatemnt, daclatasvir, asunaprevir.